Advertisement
Screener

PALISADE BIO, INC. (PALI) ROI

PALISADE BIO, INC. ROI

Return on investment (ROI), also called return on invested capital, is the profit a company earns for every dollar of long-term capital from both lenders and shareholders, shown as a percentage. It is net income divided by long-term debt plus shareholder equity, and the table shows both amounts. Because debt is included in the base, ROI does not rise just because a company replaces equity with borrowing, which sets it apart from ROE. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • PALISADE BIO, INC. roi for the quarter ending 2021-12-31 was -357.17%, a 634.99% decline year-over-year.
  • PALISADE BIO, INC. roi for the quarter ending 2021-09-30 was -711.52%.
  • PALISADE BIO, INC. roi for the quarter ending 2021-06-30 was 504.19%.
  • PALISADE BIO, INC. roi for the quarter ending 2020-12-31 was 66.76%.
  • PALISADE BIO, INC. roi for fiscal 2021 was -357.17%, a 634.99% decline from fiscal 2020.
  • PALISADE BIO, INC. roi for fiscal 2020 was 66.76%.
  • PALISADE BIO, INC. roi for fiscal 2015 was -162.11%, a change of -76.73% from fiscal 2014.
  • PALISADE BIO, INC. roi for fiscal 2014 was -85.37%, a change of 37.69% from fiscal 2013.
Available history
2012-12-31 to 2021-12-31
Data captured

Historical ROI

DateROINet income 12 monthNet income 3 monthDebt plus equity
2021-12-31-357.17%-$26.62M$1.07M$7.45M
2021-09-30-711.52%-$31.93M$8.09M$4.49M
2021-06-30504.19%-$41.86M-$31.75M-$8.3M
2020-12-3166.76%-$10.32M-$4.24M-$15.46M
2016-03-31-328.17%-$22.46M-$6.61M$6.84M
2015-12-31-162.11%-$20.9M-$4.77M$12.9M
2015-09-30-120.33%-$21.64M-$5.64M$17.99M
2015-06-30-86.98%-$20.46M-$5.45M$23.52M
2015-03-31-77.05%-$21.76M-$5.05M$28.25M
2014-12-31-85.37%-$22.63M-$5.50M$26.51M
2014-09-30-76.88%-$20.43M-$4.46M$26.57M
2014-06-30-74.55%-$22.66M-$6.75M$30.4M
2014-03-31-65.30%-$22.16M-$5.92M$33.94M
2013-12-31-123.06%-$19.83M-$3.30M$16.12M
2013-09-30-120.92%-$19.24M-$6.69M$15.91M
2013-06-30-125.99%-$15.13M-$6.25M$12.01M
2013-03-31-84.99%-$11.26M-$3.59M$13.25M
2012-12-31-145.16%-$10.12M-$2.71M$6.97M

Annual ROI

DateROINet income 12 monthDebt plus equity
2021-12-31-357.17%-$26.62M$7.45M
2020-12-3166.76%-$10.32M-$15.46M
2015-12-31-162.11%-$20.9M$12.9M
2014-12-31-85.37%-$22.63M$26.51M
2013-12-31-123.06%-$19.83M$16.12M
2012-12-31-145.16%-$10.12M$6.97M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Liminatus Pharma, Inc. (LIMN)United States$0.282B
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35